Cite

    Saygin, C. et al. (n.d.). A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome. American journal of hematology. 95 (12), pp. 1457-1465. [Online].